ARS Pharmaceuticals (SPRY) News Today $4.82 +0.14 (+2.99%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$4.65▼$4.8950-Day Range$2.92▼$6.6152-Week Range$2.55▼$9.65Volume446,488 shsAverage Volume982,057 shsMarket Capitalization$462.24 millionP/E RatioN/ADividend YieldN/APrice Target$14.67 HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative SourceHeadlineCritical Analysis: ARS Pharmaceuticals (NASDAQ:SPRY) versus Allarity Therapeutics (NASDAQ:ALLR)americanbankingnews.com - November 21 at 1:44 AMARS Pharmaceuticals Stock (NASDAQ:SPRY), Analyst Ratings, Price Targets, Predictionsbenzinga.com - November 14 at 4:07 PMARS Pharmaceuticals, Inc.: ARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatesfinanznachrichten.de - November 10 at 8:41 AMARS Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - November 9 at 8:12 PMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc. (SPRY) for Potential Violations of Securities Lawsbenzinga.com - October 12 at 2:26 PMARS Pharmaceuticals Says FDA Schedules Type A Meeting For Neffy By The End Of Octobermarkets.businessinsider.com - October 6 at 2:22 PMARS Pharmaceuticals Announces Scheduling of a Type A Meeting with the U.S. FDA for neffy® (epinephrine nasal spray)finance.yahoo.com - October 6 at 9:20 AMARS Pharmaceuticals (NASDAQ: SPRY)fool.com - October 5 at 2:07 PMSHAREHOLDER ALERT: The Law Offices of Vincent Wong Investigate ARS Pharmaceuticals, Inc.(SPRY) for Potential Violations of Securities Lawsbenzinga.com - October 3 at 6:53 PMSingle and Repeat Dose Clinical Study of neffy (epinephrine nasal spray) Published in the Journal of Allergy and Clinical Immunologyfinance.yahoo.com - October 3 at 1:53 PMChief Legal Officer Alexander Fitzpatrick Buys 86,258 Shares of ARS Pharmaceuticals Incfinance.yahoo.com - October 3 at 8:52 AMARS Pharmaceuticals, Harmonic, and More Stocks See Action From Activist Investorsfinance.yahoo.com - September 29 at 9:35 PM3 Small Biotech Stocks That Could Be Starsfinance.yahoo.com - September 29 at 11:34 AMWe're Hopeful That ARS Pharmaceuticals (NASDAQ:SPRY) Will Use Its Cash Wiselyfinance.yahoo.com - September 28 at 11:45 AMAvantax Planning Partners Inc. Invests $216,000 in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)marketbeat.com - September 27 at 6:48 AMFisker, Intercept Pharmaceuticals, Immunovant And Other Big Stocks Moving Higher On Tuesdaybenzinga.com - September 26 at 12:13 PMDirector At This Health Care Company Buys $8.18M of Stockbenzinga.com - September 26 at 12:13 PMARS Pharmaceuticals' EpiPen Alternative Delayed US Approval - Two Analysts Offer Differing Viewsmsn.com - September 22 at 8:00 AMARS Pharmaceuticals (NASDAQ:SPRY) Downgraded by Leerink Partnrsmarketbeat.com - September 22 at 6:49 AMWilliam Blair Analysts Raise Earnings Estimates for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)marketbeat.com - September 22 at 6:48 AMWhat's Going On With ARS Pharmaceuticals Stock Today?markets.businessinsider.com - September 21 at 8:06 PMARS Pharmaceuticals (SPRY) Down on CRL for Nasal Sprayfinance.yahoo.com - September 21 at 3:05 PMARS Pharma (NASDAQ:SPRY) Plummets on FDA Snub for Epinephrine Nasal Spraymsn.com - September 21 at 10:04 AMFed’s Message Is Louder Than Its Rate Call. Why That’s Critical for Investors.finance.yahoo.com - September 21 at 10:04 AMWedbush Cuts ARS Pharmaceuticals (NASDAQ:SPRY) Price Target to $5.00marketbeat.com - September 21 at 8:46 AMFDA Declines to Approve Epinephrine Nasal-Spray, Asks for Additional Datamsn.com - September 20 at 6:21 PMARS Pharma shares plummet after FDA asks for extra test of nasal spraymsn.com - September 20 at 1:21 PMARS Pharmaceuticals Shares Sink to New Lows on FDA Neffy Setback >SPRYmarketwatch.com - September 20 at 1:21 PMARS Pharma hits 52-week low as William Blair downgrades on FDA snubmsn.com - September 20 at 1:21 PMmarketbeat.com - September 20 at 9:48 AMBiggest stock movers today: Instacart, ARS Pharmaceuticals and moremsn.com - September 20 at 8:21 AMARS Pharmaceuticals Shares Sink Premarket as FDA Rejects Neffy Spray >SPRYmarketwatch.com - September 20 at 8:21 AMARS Pharma : FDA Issues CRL For Nasal Spray NDA With Request For Addl Study; Stock Downmarkets.businessinsider.com - September 20 at 3:20 AMUS FDA declines to approve ARS' emergency nasal spray for allergic reactionsreuters.com - September 20 at 3:20 AMFDA Issues Complete Response Letter for neffy® (epinephrine nasal spray) New Drug Application with Request for Additional Studyfinance.yahoo.com - September 20 at 3:20 AMRoyce & Associates LP Acquires Shares of 303,900 ARS Pharmaceuticals, Inc. (NASDAQ:SPRY)marketbeat.com - September 13 at 10:43 AM2,006,451 Shares in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Acquired by Baker BROS. Advisors LPmarketbeat.com - September 12 at 5:40 AMARS Pharmaceuticals (NASDAQ:SPRY) Shares Gap Up on Insider Buying Activitymarketbeat.com - September 1 at 10:23 AMARS Pharmaceuticals Prepares For Neffy's Anticipated Launchmsn.com - August 16 at 5:23 PMARS Reports Second Quarter 2023 Financial Results and Provides Business Updatesfinance.yahoo.com - August 10 at 5:17 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Director Laura Shawver Sells 26,520 Sharesmarketbeat.com - July 6 at 11:18 PMARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Expected to Post Q3 2023 Earnings of ($0.19) Per Sharemarketbeat.com - June 23 at 7:54 AMSVB Securities Sticks to Its Buy Rating for ARS Pharmaceuticals (SPRY)markets.businessinsider.com - June 22 at 9:07 AMAnalyst Expectations for ARS Pharmaceuticals's Futuremarkets.businessinsider.com - June 21 at 1:40 PMARS Pharmaceuticals Announces PDUFA Date Extension for neffy® (Intranasal (IN) Epinephrine) for the Treatment of Allergic Reactions (Type 1), Including Anaphylaxisfinance.yahoo.com - June 20 at 1:42 PMLaura Shawver Sells 73,059 Shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Stockmarketbeat.com - June 2 at 10:47 PMQ2 2023 Earnings Estimate for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Issued By Wedbushmarketbeat.com - May 22 at 1:27 AMWedbush Keeps Their Buy Rating on ARS Pharmaceuticals (SPRY)markets.businessinsider.com - May 18 at 7:11 AMARS Pharma (SPRY) Gets FDA Panel Vote for Epinephrine Nasal Sprayfinance.yahoo.com - May 15 at 5:46 PMARS Pharmaceuticals: Potential Revolution In Allergy Treatment With Neffymsn.com - May 15 at 12:46 PM Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address SPRY Media Mentions By Week SPRY Media SentimentLearn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. SPRY News Sentiment▼0.940.87▲Average Medical News Sentiment SPRY News CoverageLearn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. SPRY Articles This Week▼11▲SPRY Articles Average Week Get ARS Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for SPRY and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: RAPT News Today LQDA News Today PHAT News Today PHVS News Today BCYC News Today EWTX News Today ICVX News Today ORIC News Today WVE News Today ORTX News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat Originals This page (NASDAQ:SPRY) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ARS Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.